A Rare Disease CRO
Everyone Deserves to be Well
ARG is a rare disease-focused contract research organization that provides comprehensive clinical program development services ranging from pre-launch consulting to commercialization. Founded in 2004, ARG has experienced consistent growth across the globe, expanding our reach to include drug and device trial management in diverse and wide-ranging therapeutic areas. ARG has remained true to our original vision: every project is highly significant and visible, delivered through strategic collaboration with partners. ARG is rare for a reason: we successfully operationalize orphan development projects because we believe everyone deserves to be well.
The Journey to Droxidopa
Chelsea Therapeutics was in the process of licensing droxidopa for treating neurogenic orthostatic hypotension, but the study suffered from low patient recruitment. ARG was brought in to improve enrollment.
LEARN MORE ›
A Life-saving Drug's Race to America
Cinryze is used to treat hereditary angioedema, or HAE, a genetic defect that results in dysfunctional C1 esterase inhibitor. ARG helped Lev Pharmaceuticals conduct the trials and bring the drug to the market after a troubled history.
LEARN MORE ›
fuels passion and progress
The clinic isn’t the only place where we make strides. ARG works with a variety of rare disease organizations, advancing care alongside other dedicated individuals who advocate research.